GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (STU:HBI) » Definitions » Cyclically Adjusted Price-to-FCF

Harvard Bioscience (STU:HBI) Cyclically Adjusted Price-to-FCF : 33.00 (As of Jun. 20, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Harvard Bioscience Cyclically Adjusted Price-to-FCF?

As of today (2024-06-20), Harvard Bioscience's current share price is €2.64. Harvard Bioscience's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.08. Harvard Bioscience's Cyclically Adjusted Price-to-FCF for today is 33.00.

The historical rank and industry rank for Harvard Bioscience's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

STU:HBI' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 10.22   Med: 21.34   Max: 81.8
Current: 31.32

During the past years, Harvard Bioscience's highest Cyclically Adjusted Price-to-FCF was 81.80. The lowest was 10.22. And the median was 21.34.

STU:HBI's Cyclically Adjusted Price-to-FCF is ranked better than
58.9% of 236 companies
in the Medical Devices & Instruments industry
Industry Median: 41.72 vs STU:HBI: 31.32

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Harvard Bioscience's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €0.014. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €0.08 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Harvard Bioscience Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Harvard Bioscience's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience Cyclically Adjusted Price-to-FCF Chart

Harvard Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.29 39.45 73.52 37.66 57.07

Harvard Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.12 65.94 48.13 57.07 45.16

Competitive Comparison of Harvard Bioscience's Cyclically Adjusted Price-to-FCF

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Bioscience's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's Cyclically Adjusted Price-to-FCF falls into.



Harvard Bioscience Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Harvard Bioscience's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=2.64/0.08
=33.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Bioscience's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Harvard Bioscience's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.014/131.7762*131.7762
=0.014

Current CPI (Mar. 2024) = 131.7762.

Harvard Bioscience Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.021 100.560 0.028
201409 0.003 100.428 0.004
201412 0.012 99.070 0.016
201503 -0.043 99.621 -0.057
201506 -0.027 100.684 -0.035
201509 -0.019 100.392 -0.025
201512 0.029 99.792 0.038
201603 -0.025 100.470 -0.033
201606 0.019 101.688 0.025
201609 0.075 101.861 0.097
201612 0.033 101.863 0.043
201703 -0.023 102.862 -0.029
201706 0.006 103.349 0.008
201709 0.046 104.136 0.058
201712 -0.028 104.011 -0.035
201803 -0.001 105.290 -0.001
201806 0.027 106.317 0.033
201809 -0.039 106.507 -0.048
201812 0.059 105.998 0.073
201903 0.044 107.251 0.054
201906 0.009 108.070 0.011
201909 0.067 108.329 0.082
201912 0.042 108.420 0.051
202003 0.062 108.902 0.075
202006 0.048 108.767 0.058
202009 0.023 109.815 0.028
202012 0.046 109.897 0.055
202103 0.016 111.754 0.019
202106 0.012 114.631 0.014
202109 -0.024 115.734 -0.027
202112 -0.005 117.630 -0.006
202203 -0.054 121.301 -0.059
202206 -0.014 125.017 -0.015
202209 0.005 125.227 0.005
202212 0.055 125.222 0.058
202303 0.035 127.348 0.036
202306 0.064 128.729 0.066
202309 0.087 129.860 0.088
202312 0.070 129.419 0.071
202403 0.014 131.776 0.014

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Harvard Bioscience  (STU:HBI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Harvard Bioscience Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Bioscience (STU:HBI) Business Description

Traded in Other Exchanges
Address
84 October Hill Road, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.